Identification of a haemolysin-like peptide with antibacterial activity using the draft genome sequence of Staphylococcus epidermidis strain A487

FEMS Immunology and Medical Microbiology

Volumn 62, Issue 3, 2011, Pages 273-282

  Al Mahrous, Mohammed M ^a   Jack, Ralph W ^b   Sandiford, Stephanie K ^a   Tagg, John R ^b   Beatson, Scott A ^c   Upton, Mathew ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibacterial peptides; Coagulase negative staphylococci; Haemolysin; Heat labile neutralizing agent; MRSA; Purification

Indexed keywords

HEMOLYSIN; PEPTIDE DERIVATIVE;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL STRAIN; MOLECULAR WEIGHT; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STAPHYLOCOCCUS EPIDERMIDIS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHROMATOGRAPHY, LIQUID; GENOME, BACTERIAL; HEMOLYSIN PROTEINS; HOT TEMPERATURE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STABILITY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN; STAPHYLOCOCCUS EPIDERMIDIS; TANDEM MASS SPECTROMETRY;

EID: 79960378413     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00811.x     Document Type: Article

References (39)

1. Al-Mahrous M, Sandiford SK, Tagg JR & Upton M (2010) Purification and characterisation of a novel delta-lysin variant that inhibits Staphylococcus aureus and has limited hemolytic activity. Peptides 31: 1661-1668.
2. Avgustin J & Grabnar M (2007) Sequence analysis of the plasmid pColG from the Escherichia coli strain CA46. Plasmid 57: 89-93.
3. Begley M, Cotter P, Hill C & Ross R (2009) Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl Environ Microb 75: 5451-5460.
4. Boerlin P, Chen S, Colbourne J, Johnson R, De Grandis S & Gyles C (1998) Evolution of enterohemorrhagic Escherichia coli haemolysin plasmids and the locus for enterocyte effacement in shiga toxin-producing E. coli. Infect Immun 66: 2553-2561.
5. Breukink E & de Kruijff B (2006) Lipid-II as a target for antibiotics. Nat Rev Drug Discov 5: 321-332.
6. Breukink E, Wiedemann I, van Kraaij C, Kuipers O, Sahl H & de Kruijff B (1999) Use of the cell wall precursor lipid-II by a pore-forming peptide antibiotic. Science 286: 2361-2364.
7. Brown K & Hancock R (2006) Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 18: 24-30.
8. Christie R, Athkins N & Munch-Petersen E (1944) A note on the lytic phenomenon shown by group B streptococci. Aust J Exp Biol Med 22: 197-200.
9. Crupper S & Iandolo J (1996) Purification and partial characterisation of a novel antibacterial agent (Bac1829) produced by Staphylococcus aureus KSI1829. Appl Environ Microb 62: 3171-3175.
10. Daly K, Upton M, Sandiford S et al. (2010) Production of the Bsa lantibiotic by community-acquired Staphylococcus aureus strains. J Bacteriol 192: 1131-1142.
11. DeHart H, Heath H, Heath L, LeBlanc P & Sloan G (1995) The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus. Appl Environ Microb 61: 1475-1479.
12. Dhople V & Nagaraj R (2005) Conformation and activity of delta-lysin and its analogs. Peptides 26: 217-225.
13. Fitton J, Dell A & Shaw W (1980) The amino acid sequence of the delta haemolysin of Staphylococcus aureus. FEBS Lett 115: 209-212.
14. Gilmore M, Segarra R, Booth M, Bogie C, Hall L & Clewell D (1994) Genetic structure of the Enterococcus faecalis plasmid pAD1-encoded cytolytic toxin system and its relationship to lantibiotic determinants. J Bacteriol 176: 7335-7344.
15. Hancock R (1997) Peptide antibiotics. Lancet 349: 418-422.
16. Hancock R (1998) The therapeutic potential of cationic peptides. Expert Opin Inv Drug 7: 167-174.
17. Hancock R & Lehrer R (1998) Cationic peptides: a new source of antibiotics. Trends Biotechnol 16: 82-88.
18. He Z, Kisla D, Zhang L, Yuan C, Green-Church K & Yousef A (2007) Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin. Appl Environ Microb 73: 168-178.
19. Jack R, Tagg J & Ray B (1995) Bacteriocins of Gram-positive bacteria. Microbiol Rev 59: 171-200.
20. Jack R, Sahl H & Bierbaum G (1998) Lantibiotics and Related Peptides. Springer-Verlag, Berlin.
21. Janzon L & Arvidson S (1990) The role of the delta-lysin gene (hld) in the regulation of virulence genes by the accessory gene regulator (agr) in Staphylococcus aureus. EMBO J 9: 1391-1399.
22. Kokai-Kun J, Walsh S, Chanturiya T & Mond J (2003) Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Ch 47: 1589-1597.
23. Leclercq R, Derlot E, Duval J & Courvalin P (1988) Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New Engl J Med 319: 157-161.
24. Mak P, Maszewska A & Rozalska M (2008) The amino acid sequences and activities of synergistic haemolysins from Staphylococcus cohnii. FEMS Microbiol Lett 287: 230-235.
25. Navarro M, Huttner B & Harbarth S (2008) MRSA control in the 21st century: beyond the acute care hospital. Curr Opin Infect Dis 21: 372-379.
26. Piccinini R & Zecconi A (2001) Relationship among plasmids recovered from Staphylococcus aureus, milk leukocytes, and antimicrobial resistance. J Dairy Sci 84: 2641-2648.
27. Ruef C (2004) Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32: 315-327.
28. Santamour B (2008) As a superbug spreads, so does misinformation. Hosp Health Network 82: 36-40.
29. Steinkraus G, White R & Friedrich L (2007) Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 60: 788-794.
30. Stevens D (2006) The role of vancomycin in the treatment paradigm. Clin Infect Dis 42: S51-S57.
31. Sweeney P & Walker J (1993) Proteolytic enzymes for peptide production. Enzymes of Molecular Biology, Vol. 16 (Burrell MM, ed.), pp. 277-303. Humana Press, Totowa, NJ.
32. Tagg J & Bannister L (1979) Fingerprinting beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitory substance. J Med Microbiol 12: 397-411.
33. Tagg J, Dajani A & Wannamaker L (1976) Bacteriocins of Gram-positive bacteria. Microbiol Mol Biol R 40: 722-756.
34. Tegmark K, Morfeldt E & Arvidson S (1998) Regulation of agr-dependent virulence genes in Staphylococcus aureus by RNAIII from coagulase-negative staphylococci. J Bacteriol 180: 3181-3186.
35. Verdon J, Berjeaud J, Lacombe C & Hechard Y (2008) Characterisation of anti-Legionella activity of warnericin RK and delta-lysin I from Staphylococcus warneri. Peptides 29: 978-984.
36. Verdon J, Girardin N, Lacombe C, Berjeaud J & Hechard Y (2009) Delta-haemolysin, an update on a membrane-interacting peptide. Peptides 30: 817-823.
37. Waalwijk C, de Graaff J & MacLaren D (1984) Physical mapping of haemolysin plasmid pCW2, which codes for virulence of a nephropathogenic Escherichia coli strain. J Bacteriol 159: 424-426.
38. Wells J & McLuckey S (2005) Collision-induced dissociation (CID) of peptides and proteins. Methods Enzymol, Vol. 402 (Burlingame AL, ed.), pp. 148-185. Academic Press, New York.
39. Yianni Y, Fitton J & Morgan C (1986) Lytic effects of melittin and delta-haemolysin from Staphylococcus aureus on vesicles of dipalmitoylphosphatidylcholine. Biochim Biophys Acta 856: 91-100.